Home

Zentalis Pharmaceuticals, Inc. - common stock (ZNTL)

1.7400
+0.0800 (4.82%)

Zentalis Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for the treatment of cancer

The company's expertise lies in its ability to identify and target specific molecular pathways that drive cancer growth and progression. Zentalis is dedicated to advancing a pipeline of small molecules designed to address high unmet medical needs in oncology. Through a combination of scientific rigor and a commitment to patient care, the company aims to deliver effective treatment options that can improve outcomes for individuals battling cancer.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close1.660
Open1.700
Bid1.730
Ask1.750
Day's Range1.690 - 1.790
52 Week Range1.660 - 18.07
Volume3,138,861
Market Cap78.39M
PE Ratio (TTM)-0.6988
EPS (TTM)-2.5
Dividend & YieldN/A (N/A)
1 Month Average Volume2,762,454

News & Press Releases

These stocks that are showing activity before the opening bell on Wednesday.chartmill.com
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.
Via Chartmill · January 29, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · January 29, 2025
FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancersbenzinga.com
The FDA has lifted the partial clinical hold on Zentalis Pharmaceuticals' azenosertib studies. Zentalis plans to work with trial investigators to continue development while presenting additional data later this year.
Via Benzinga · September 16, 2024
Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQZNTL) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”).
By Newman Ferrara LLP · Via Business Wire · August 19, 2024
(ZNTL) - Analyzing Zentalis Pharma's Short Interestbenzinga.com
Via Benzinga · June 21, 2024
Analyst Expectations for Zentalis Pharma's Futurebenzinga.com
Via Benzinga · November 7, 2023
Where Zentalis Pharma Stands With Analystsbenzinga.com
Via Benzinga · August 10, 2023
Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. (“Zentalis” or “the Company”) (NASDAQZNTL). Investors who purchased Zentalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ZNTL.
ZNTL Stock Earnings: Zentalis Pharma Misses EPS for Q2 2024investorplace.com
ZNTL stock results show that Zentalis Pharma missed analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 9, 2024
ZNTL Investors Have Opportunity to Join Zentalis Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. (“Zentalis” or “the Company”) (NASDAQZNTL) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · August 1, 2024
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22talkmarkets.com
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of June 17-21, 2024.
Via Talk Markets · June 22, 2024
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · June 20, 2024
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · June 19, 2024
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · June 19, 2024
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com
Via Benzinga · June 18, 2024
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · June 18, 2024
Why Is Small-Cap Cancer-Focused Zentalis Pharma Stock Trading Lower On Tuesday?benzinga.com
Zentalis Pharmaceuticals announced the FDA's partial clinical hold on azenosertib studies due to recent patient deaths.
Via Benzinga · June 18, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · June 18, 2024
ZNTL Stock Earnings: Zentalis Pharma Beats EPS, Beats Revenue for Q1 2024investorplace.com
ZNTL stock results show that Zentalis Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 7, 2024
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Via Benzinga · March 28, 2024
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potentialtalkmarkets.com
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
Via Talk Markets · February 22, 2024
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
Immunome, Inc. (Nasdaq: IMNM) and Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), today announced that they have entered into an exclusive, worldwide license agreement under which Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug conjugate (ADC) with best-in-class potential on track for IND submission in 1Q 2025, and Zentalis’ proprietary ADC platform technology.
By Immunome, Inc. · Via Business Wire · January 8, 2024
Morgan Stanley Maintains Overweight Rating for Zentalis Pharma: Here's What You Need To Knowbenzinga.com
Via Benzinga · November 7, 2023
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · November 6, 2023
TreeHouse Foods, EchoStar, Hilton Grand Vacations, EchoStar And Other Big Stocks Moving Lower On Mondaybenzinga.com
U.S. stocks traded higher, with the Dow Jones gaining around 25 points on Monday. Here are some big stocks recording losses in today’s session.
Via Benzinga · November 6, 2023